Background
==========

Breast cancer is one of the major cancers around the world but its etiology is still not well understood. Only about 50% of the disease is associated with known risk factors including high-penetrance genes and lifestyle factors. Candidate low-penetrance genes are involved in a variety of pathways; for example, DNA damage by free radicals. The enzymes involved in this mechanism are *N*-acetyltransferase2 (NAT2) and manganese superoxide dismutase (MnSOD). NAT2 catalyzes acetylation of aromatic amines and hydrasines and forms of free radicals, and MnSOD catalyzes their dismutation. Genes *TGFBR1*and *RGS19IP1*encode proteins that take part in transforming growth factor beta signaling, mainly resulting in inhibition of cell proliferation. The first exon of *TGFBR1*contains a polymorphic GCG repeat; (GCG)~6~was previously reported as the tumor susceptibility allele associated with some types of cancer. The 5\'-untranslated region of *RGS19IP1*contains a CGG repeat, the polymorphism of which had not been studied before.

Methods
=======

SNPs of *NAT2*and *MnSOD*were detected by the PCR-RFLP method, alleles of *TGFBR1*were detected by electrophoresis and *RGS19IP1*alleles were detected by fragment analysis on 123 breast cancer cases and 121 controls.

Results
=======

We have assessed the frequency of frequent allelic variants of *NAT2*(*NAT2\*4*\[wild type\], *NAT2\*5*\[T341C\], *NAT2\*6*\[G590A\], *NAT2\*7*\[G857A\]). The *NAT2\*11*allele in the Russian sample was found as well. Our breast cancer cases had statistically significant positive association with *NAT2\*6/\*6*or *NAT2\*11*(33.4% vs 11.0%; *P*= 0.0005; OR = 3.06 \[95% CI = 1.62-5.77\], cases vs controls). The frequency of the *NAT2\*5*and *NAT2\*7*alleles was not significantly elevated in our breast cancer sample compared with controls. The *MnSOD*gene was studied for polymorphism of valine (V) versus alanine (A) in the leader peptide at position 16. The V/V genotype (MroNI^-/-^) was associated with decreased risk of breast cancer (24.4% vs 38.0%; *P*= 0.0268; OR = 0.53 \[95% CI = 0.03-0.91\]). The risk of breast cancer decreased in a combination of *NAT2\*4*, *NAT2\*5*or *NAT2\*7*alleles and V/V genotype *MnSOD*(20.3% vs 36.1%; *P*= 0.0068; OR = 0.45 \[95% CI 0.25-0.79\]).

Our breast cancer cases had statistically significant positive association with the (GCG)~6~allele of *TGFBR1*(13.8% vs 6.1%, *P*= 0.016, OR = 2.47 \[95% CI = 1.21-5.07\]). Statistically significant positive association with the genotype *6A/9A*(20.2% vs 11.6%, α = 0.05, OR = 1.92 \[95% CI = 1.05-3.49\]) was also revealed. Genotype *6A/9A*can be used as a predisposition marker, the relative risk for this genotype carrier being increased 1.7-fold. We have identified a polymorphism of the CGG repeat in *RGS19IP1*with at least eight alleles: four major (CGG~10~--CGG~13~), with frequencies 20.4%, 41.6%, 27.6% and 10.4%, respectively; the rest of the alleles are rare with overall frequency of 1% in control; heterozygosity, 0.729. Our breast cancer cases had statistically significant positive association with the rare alleles (4.7% vs 1%, *P*= 0.01, OR = 4.92 \[95%, CI = 1.42-17.1\]).

Conclusion
==========

All polymorphisms tested could be used as a panel of markers for detecting families and individuals of high breast cancer risk.
